FIP1L1::PDGFRA
1 EU-approved indication of 1 drug needs a FIP1L1::PDGFRA result, in 1 tumour type, most of them in myeloid/lymphoid neoplasms with eosinophilia and TK fusions.
Approved indications1
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| Myeloid/lymphoid neoplasms with eosinophilia and TK fusions1 | ||||
Glivec | FIP1L1-PDGFRalpha rearrangement | Monotherapy | Any line advanced | None |
FIP1L1::PDGFRA by tumour
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Imatinib (Glivec)
adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.